L7 Informatics and Triumvira Immunologics Announce Agreement to Digitalize Manufacturing of Next-Generation Cell Therapies

Clinical-stage biotech to implement a unified platform with a single data fabric versus point solutions

AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- L7 Informatics, the leader in DATA+INTELLIGENCE for the scientific enterprise, and Triumvira Immunologics ("Triumvira") today announced an agreement to implement L7|ESP at Triumvira to enhance the digitalization of its manufacturing of next-generation cell therapies. Triumvira is a clinical-stage company developing novel, targeted autologous, and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.

Instead of using a siloed and costly point solution approach, Triumvira will implement L7|ESP to drive early integration of automation to support Triumvira's manufacturing scalability with a lower cost of goods and improved reproducibility and consistency. L7|ESP will also enable remote monitoring and proactive data management.

"With early incorporation of scalable automation, we can facilitate the availability of treatment to patients and decrease the time to market. Having a unified platform like L7|ESP, we can avoid having to implement several separate point solutions, which in turn saves us valuable time and energy," explained Donna Rill, Chief Technology Officer of Triumvira. "In addition to being the first company in the U.S. to dose a patient with a therapy manufactured with Lonza's Cocoon® platform, this new agreement is part of our broader strategy to address challenges in manufacturing and delivering autologous cell therapies to patients by being at the forefront of innovation."

L7|ESP is a unified and composable platform with a single data fabric that reduces the total cost of operations while enabling the digital transformation of biologics operations, including research, process development, clinical operations, manufacturing, and quality control. The platform is compliant with the U.S. Food and Drug Administration and comes with several pre-built, best-in-class applications. Additionally, L7| ESP's REST API library and Python SDK enable flexibility and extensibility to meet customer-specific requirements. Triumvira will go live with the L7|ESP Platform (including the Research, Development, and Lab packages), L7|HUB, and L7|Intelligence.

"Triumvira completely understands the power of early integration of digital automation and the need for a single data fabric to support a successful path to commercialization," said Vasu Rangadass, Ph.D., President & CEO of L7 Informatics. "This requires an integrated system approach like L7|ESP which offers robust flexibility and power. L7 enables you to start small and scale quickly from research to commercialization."

About L7 Informatics:
L7 Informatics reimagines data intelligence for modern life sciences and healthcare organizations, optimizing the flow of information between processes and people, unlocking innovation at every stage of the clinical, research, and manufacturing value chains. Our comprehensive operating environment and software stack bring flexible, secure, and collaborative data+intelligence to life sciences organizations. Our end-to-end transformation engine helps solve the challenges of today and realize the opportunities of tomorrow.

About Triumvira Immunologics:
Triumvira Immunologics, Inc. ("Triumvira") is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

SOURCE L7 Informatics